Skip to main content

VALIDACION DEL PROYECTO MIRTO (MODELING THE INDIVIDUAL RISK OF THROMBOSIS IN ONCOLOGY)

PI17/00059

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre HOSPITAL DE LA SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk

  • López, Sonia|||0000-0002-5023-5153
  • Martinez-Perez, Angel|||0000-0002-5934-1454
  • Rodriguez-Rius, Alba
  • Viñuela, Ana|||0000-0003-3771-8537
  • Brown, Andrew A.
  • Martin-Fernandez, Laura|||0000-0002-8909-508X
  • Vilalta, Noelia|||0000-0002-3961-3563
  • Arús, Marc
  • Panousis, Nikolaos I.
  • Buil, Alfonso|||0000-0002-3097-1014
  • Sabater-Lleal, Maria|||0000-0002-0128-379X
  • Souto, Juan Carlos|||0000-0003-2092-5142
  • Dermitzakis, Emmanouil T.|||0000-0002-9302-6490
  • Soria Fernández, José Manuel|||0000-0002-6226-4293
Plasma cell-free DNA (cfDNA) is a surrogate marker of neutrophil extracellular traps (NETs) that contribute to immunothrombosis. There is growing interest about the mechanisms underlying NET formation and elevated cfDNA, but little is known about the factors involved.We aimed to identify genes involved in the regulation of cfDNA levels using data from the Genetic Analysis of Idiopathic Thrombophilia (GAIT-2) Project. Imputed genotypes, whole blood RNA-Seq data, and plasma cfDNA quantification were available for 935 of the GAIT-2 participants from 35 families with idiopathic thrombophilia. We performed heritability and GWAS analysis for cfDNA. The heritability of cfDNA was 0.26 (p 3.7106), while the GWAS identified a significant association (rs1687391, p 3.551010) near the ORM1 gene, on chromosome 9. An eQTL (expression quantitative trait loci) analysis revealed a significant association between the lead GWAS variant and the expression of ORM1 in whole blood (p 6.14109). Additionally, ORM1 expression correlated with levels of cfDNA (p 4.38104). Finally, genetic correlation analysis between cfDNA and thrombosis identified a suggestive association (?g 0.43, p 0.089). All in all, we show evidence of the role of ORM1 in regulating cfDNA levels in plasma, which might contribute to the susceptibility to thrombosis through mechanisms of immunothrombosis.